Home » BioMerieux Spends $60M to Acquire Private Molecular Dx Firm

BioMerieux Spends $60M to Acquire Private Molecular Dx Firm

Sep 11, 2008
NEW YORK (GenomeWeb News) – BioMerieux today announced that is has acquired privately held molecular diagnostics firm AviaraDx for $60 million.
 
San Diego-based AviaraDx makes tests — the CancerTYPE ID and Breast Cancer IndexSM — that are used for the molecular classification of cancers and to aid oncologists in making therapeutic decisions. BioMerieux said that with the acquisition it gains validated cancer biomarkers as well as capabilities in gene expression profiling in tissues for oncology applications.
 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The Scan

Here We Are Again

American scientists find themselves once again warning the Trump administration not to dismiss science, the New Yorker report.

In the Pink

A new study suggests CRISPR could be used to save coral reefs from dying off, Forbes reports.

All Tied Up in a Bow

Researchers have found that the i-motif shape of DNA previously observed in the lab also exists in human cells, and that it may serve a purpose.

This Week in PNAS

In PNAS this week: a genomic, transcriptomic, and metabolomic analysis of the tea plant, Arabidopsis thaliana's adaptations to specific local environments, and more.

Sponsorships

Privacy Policy.  Copyright © 2018 GenomeWeb LLC.  All Rights Reserved.